Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.
Relapsed and Refractory Multiple Myeloma
DRUG: anitocabtagene-autoleucel
Incidence of treatment-emergent adverse events (TEAEs), including DLT(s), 24 months|Establish the RP2D of the investigational agent, 24 months
Best overall response (BOR) by International Myeloma Working Group (IMWG) Consensus Criteria, 24 months|Overall Response Rate (ORR) by IMWG Consensus Criteria, 24 months|PK Parameter for Anitocabtagene-Autoleucel: Cmax, Cmax is defined as the maximum observed concentration of drug., Day 1 up to 24 months|PK Parameter for Anitocabtagene-autoleucel: Tmax, Tmax is defined as the time (observed time point) of Cmax., Day 1 up to 24 months|PK Parameter for Anitocabtagene-Autoleucel: Area under the curve (AUC), AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption., Day 1 up to 24 months
Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.